NCT06780943 Quantification of Motor Compensation Following Biomechanical, Proprioceptive and Physiological Alterations Post-lower Limb Amputation.
| NCT ID | NCT06780943 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Nīmes |
| Condition | Amputation |
| Study Type | OBSERVATIONAL |
| Enrollment | 75 participants |
| Start Date | 2025-05-06 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 75 participants in total. It began in 2025-05-06 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lower limb amputation causes segmental loss that alters locomotor organization. The human body, designed to function in a multisegmental manner, must adapt to this new configuration where segments are missing, depending on the level of amputation. These adaptations are directly linked to the biomechanical, physiological and proprioceptive alterations caused by the loss of the amputated segments. Without mechanoreceptive afferents essential for regulating locomotion, the sensory system uses alternative information to maintain efficient locomotor function. The prosthesis partially compensates, but remains limited on the biomechanical and proprioceptive levels. Current prosthetic technologies, inspired by biomimicry, aim to imitate evolutionary solutions to restore walking, although current algorithms do not allow real-time modulation. This research aims to characterize post-amputation locomotor adaptations through biomechanical, physiological and proprioceptive exploration to develop a "locomotor characterization" model. The study authors hypothesize that the post-amputation alterations are exacerbated in contexts of continuous and discontinuous constraints (e.g., ascent/descent and destabilization), and that the addition of a prosthesis, although inspired by biomimicry, only restores partial compensation of locomotor functions.
Eligibility Criteria
Inclusion Criteria: * The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * Persons with unilateral transtibial or transfemoral amputees followed in the MPR department at the Nîmes University Hospital, RRL department, Grau du Roi University Rehabilitation Hospital. * All etiologies: vascular, traumatic and septic. * Adapted equipment validated by the rehabilitation doctor. * Able to walk for 5 minutes on a treadmill without technical assistance Inclusion criteria specific to healthy volunteers: * Adults (\>18 years old) and under 40 years old * Able to walk for 5 minutes on a treadmill without technical assistance. * Body mass index between 18 and 25 Exclusion Criteria: * The patient is participating in an interventional or a drug/medical device study, or is in a period of exclusion determined by a previous study * The patient unable to express consent * It is impossible to give the patient informed information * The patient is under safeguard of justice or state guardianship * Patient who has already been included in this study. * Pregnant, parturient or breastfeeding patient. * Appearance of a stump wound during the study requiring unloading. * Patient for whom the implementation of vibration stimulation is not possible Exclusion criteria for amputee patients: * Patient suffering from uncorrected or untreated visual disorders. * Patient with major cognitive disorders (MoCA \<23). * Patient with vestibular disorders or uncontrolled epilepsy. * Patient with an unhealed amputation stump. * Patient with a weight \> 135kg or \< 20kg * Patients with a FAC of 1 (i.e. patients who need firm and continuous assistance from a person to support their weight and maintain balance) or less. * Sensory impairment that makes it impossible to perceive stimulation * Significantly reduced bone density * Patient in whom it is impossible to correctly adjust the GRAIL System harness to the corresponding body part due to: * Body shape * Colostomy bags * Skin lesions that cannot be adequately protected. * Any other reason that prevents a good, painless adjustment of the harness. * Patient in whom it is impossible to correctly adjust the CON-TREX System: * Body shape * Colostomy bags * Skin lesions that cannot be adequately protected. * Any other reason that prevents a good, painless adjustment of the support systems. Exclusion criteria for healthy volunteers: * History of significant injury or surgery affecting the lower limbs (such as hip or knee replacement or knee/ankle ligament reconstruction) that could impact walking * History of neurological or psychiatric disorders that could affect locomotion or the processing of sensorimotor information. * Drug treatments affecting locomotion: drugs likely to alter walking or balance, such as sedatives, muscle relaxants or neuroleptics.
Contact & Investigator
Eric Pantera
PRINCIPAL INVESTIGATOR
CHU de Nimes
Frequently Asked Questions
Who can join the NCT06780943 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Amputation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06780943 currently recruiting?
Yes, NCT06780943 is actively recruiting participants. Contact the research team at eric.pantera@chu-nimes.fr for enrollment information.
Where is the NCT06780943 trial being conducted?
This trial is being conducted at Nîmes, France.
Who is sponsoring the NCT06780943 clinical trial?
NCT06780943 is sponsored by Centre Hospitalier Universitaire de Nīmes. The principal investigator is Eric Pantera at CHU de Nimes. The trial plans to enroll 75 participants.